According to a new market report published by Persistence Market
Research “Global Market Study on Human Insulin: Asia Pacific to
Witness fastest Growth by 2020,” the global human insulin market
was valued at USD 24,332.6 million in 2014 and was expected to grow
at a CAGR of 12.4% from 2014 to 2020, to reach an estimated value of
USD 49,197.3 million in 2020.
Globally, the human
insulin market is witnessing significant growth due to increasing
prevalence of diabetes and increasing awareness among people about
diabetes care. In addition, technological advancements in insulin
delivery devices and increasing prevalence of lifestyle related
disorders such as obesity are also driving the growth of the market.
However, uneven pricing and limited access to human insulin in
emerging countries such as Brazil, India, and China are inhibiting
the growth of the human insulin market. In addition, strict
regulatory requirements for drug approval are also restraining the
growth of the market. The global human insulin market was anticipated
to grow from an estimated USD 24,332.6 million in 2014 to USD
49,197.3 million in 2020 at a CAGR of 12.4% during the forecast
period.
In North America, increasing prevalence of diabetes with growing age
and availability of advanced human insulin infusion devices are
driving the use of human insulin in the market.
View Full Report TOC, Figures and Tables @
In addition, increasing prevalence of lifestyle associated disorders
such as obesity is also boosting the growth of the human insulin
market in this region. For instance, according to the Centers for
Diseases Control and Prevention (CDC), a U.S.-based national public
health institute, over one-third children and adolescents were obese
in 2012 in the U.S.
In Europe, the human insulin market is driven by rising aging
population and increasing prevalence of diabetes. In addition, in
Germany the market is evolving due to rising prevalence of diabetes
and increasing awareness among people about diabetes care. However,
in Asia-Pacific the growth for human insulin is much higher than
developed countries due to increasing prevalence of diabetes and
increasing government initiatives for improving healthcare.
Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua
Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc.,
Pfizer, Inc., Wockhardt, Julphar, Bristol-Myers Squibb Company,
GlaxoSmithKline Plc and Oramed Pharmaceuticals, Inc. are some of the
major players in human insulin market.
Browse Report Overview @
No comments:
Post a Comment